Published in Small on August 27, 2013
Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field. Int J Nanomedicine (2014) 0.93
Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev (2014) 0.90
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. ACS Nano (2015) 0.85
HER-2/neu targeted delivery of a nanoprobe enables dual photoacoustic and fluorescence tomography of ovarian cancer. Nanomedicine (2013) 0.82
Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Front Oncol (2014) 0.82
Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor. J Surg Res (2014) 0.79
Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer. Semin Radiat Oncol (2015) 0.78
Optical imaging of ovarian cancer using HER-2 affibody conjugated nanoparticles. Methods Mol Biol (2015) 0.76
Radiolabeled theranostics: magnetic and gold nanoparticles. Bioimpacts (2016) 0.75
IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer. Proc SPIE Int Soc Opt Eng (2016) 0.75
Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer. J Ovarian Res (2016) 0.75
Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. Sci Rep (2016) 0.75
Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncol Lett (2017) 0.75
Cancer of the ovary. N Engl J Med (2004) 11.21
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med (2003) 9.09
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Shedding light onto live molecular targets. Nat Med (2003) 8.47
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med (2006) 7.05
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett (2009) 4.45
Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer (2005) 3.20
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol (2009) 2.89
A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res (2003) 2.55
Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res (2006) 2.46
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun (Camb) (2004) 2.24
Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004) 2.06
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol (2008) 1.94
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res (1990) 1.75
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med (2010) 1.75
Nanoparticle imaging of integrins on tumor cells. Neoplasia (2006) 1.70
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res (2007) 1.67
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer (2006) 1.62
Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J Control Release (2010) 1.58
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology (2009) 1.47
Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res (2010) 1.44
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials (2009) 1.42
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One (2007) 1.29
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol (2010) 1.26
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med (2009) 1.23
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol (2005) 1.13
Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials (2010) 1.11
A dual fluorochrome probe for imaging proteases. Bioconjug Chem (2004) 1.06
Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine (2009) 1.05
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem (2008) 1.03
T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging (2011) 1.03
Ovarian cancer: progress and continuing controversies in management. Eur J Cancer (2002) 1.00
Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann Surg Oncol (1999) 0.97
HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer (2004) 0.94
Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol (1992) 0.93
Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer (2004) 0.92
Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol (1995) 0.86
Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro Oncol (2011) 0.85
Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol (1998) 0.85
Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PLoS One (2012) 0.84
MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody. Contrast Media Mol Imaging (2010) 0.84
Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol Cancer Ther (2010) 0.82
In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles. J Control Release (2012) 0.82
Pulmonary metastases in ovarian cancer. Analysis of 357 patients. Cancer (1985) 0.81
HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. Cancer Lett (1993) 0.77
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature (2007) 9.25
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
Human receptors for sweet and umami taste. Proc Natl Acad Sci U S A (2002) 5.91
The iPlant Collaborative: Cyberinfrastructure for Plant Biology. Front Plant Sci (2011) 4.16
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol (2009) 3.21
p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron (2005) 3.13
Large-scale synthesis of nearly monodisperse CdSe/CdS core/shell nanocrystals using air-stable reagents via successive ion layer adsorption and reaction. J Am Chem Soc (2003) 2.87
A taste receptor required for the caffeine response in vivo. Curr Biol (2006) 2.51
Epidemiologic features of severe fever with thrombocytopenia syndrome in China, 2011-2012. Clin Infect Dis (2013) 2.46
Endoscopic sealing of pancreatic fistula by using N-butyl-2-cyanoacrylate. Gastrointest Endosc (2004) 2.43
Identification of protein complexes required for efficient sister chromatid cohesion. Mol Biol Cell (2004) 2.34
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Elg1 forms an alternative RFC complex important for DNA replication and genome integrity. EMBO J (2003) 2.03
Ras induces mediator complex exchange on C/EBP beta. Mol Cell (2004) 1.98
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest (2006) 1.94
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
A detrimental mitochondrial-nuclear interaction causes cytoplasmic male sterility in rice. Nat Genet (2013) 1.92
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum Mol Genet (2003) 1.84
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
A wireless brain-machine interface for real-time speech synthesis. PLoS One (2009) 1.73
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol (2008) 1.62
Protein energetic conformational analysis from NMR chemical shifts (PECAN) and its use in determining secondary structural elements. J Biomol NMR (2005) 1.62
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58
Probabilistic Identification of Spin Systems and their Assignments including Coil-Helix Inference as Output (PISTACHIO). J Biomol NMR (2005) 1.56
Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A (2004) 1.56
Positive and negative emotional verbal stimuli elicit activity in the left amygdala. Neuroreport (2002) 1.55
Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small (2008) 1.53
Molecular mechanism for the umami taste synergism. Proc Natl Acad Sci U S A (2008) 1.53
Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med (2005) 1.53
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway. Leuk Res (2005) 1.51
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol (2005) 1.49
Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res (2005) 1.49
Light adaptation through phosphoinositide-regulated translocation of Drosophila visual arrestin. Neuron (2003) 1.48
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology (2009) 1.47
Bitter taste receptors influence glucose homeostasis. PLoS One (2008) 1.44
Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res (2010) 1.44
Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability. J Med Genet (2010) 1.43
Using human extra-cortical local field potentials to control a switch. J Neural Eng (2004) 1.42
Diethyl 3,3'-(phenyl-methyl-ene)bis-(1H-indole-2-carboxyl-ate). Acta Crystallogr Sect E Struct Rep Online (2012) 1.42
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
Extracorporeal shock wave lithotripsy is effective in treating single melamine induced urolithiasis in infants and young children. J Urol (2012) 1.38
Specific alleles of bitter receptor genes influence human sensitivity to the bitterness of aloin and saccharin. Curr Biol (2007) 1.37
Light activation, adaptation, and cell survival functions of the Na+/Ca2+ exchanger CalX. Neuron (2005) 1.37
Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res (2011) 1.36
Neurotrophic electrode: method of assembly and implantation into human motor speech cortex. J Neurosci Methods (2008) 1.34
Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med (2009) 1.33
Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression. J Biol Chem (2004) 1.33
Molecular mechanism of the sweet taste enhancers. Proc Natl Acad Sci U S A (2010) 1.32
Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) (2006) 1.32
Lsh controls Hox gene silencing during development. Proc Natl Acad Sci U S A (2007) 1.31
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
The synthesis of chitosan-based silver nanoparticles and their antibacterial activity. Carbohydr Res (2009) 1.29
Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nat Chem Biol (2010) 1.29
Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clin Cancer Res (2007) 1.29
Rational design of protein-based MRI contrast agents. J Am Chem Soc (2008) 1.28
Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-September, 2009: temporal and spatial spreading profile of the viruses in Japan. PLoS One (2010) 1.28
Epidemiologic characteristics of cases for influenza A(H7N9) virus infections in China. Clin Infect Dis (2013) 1.28
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain. Genes Dev (2005) 1.28
Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. PLoS One (2010) 1.27
Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet (2011) 1.26
Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials (2010) 1.25
The crosstalk between EGF, IGF, and Insulin cell signaling pathways--computational and experimental analysis. BMC Syst Biol (2009) 1.24
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol (2009) 1.23
Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans. J Allergy Clin Immunol (2009) 1.23
The crystal structure of human adenylate kinase 6: An adenylate kinase localized to the cell nucleus. Proc Natl Acad Sci U S A (2005) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Conjugated microporous polymers: design, synthesis and application. Chem Soc Rev (2013) 1.23
Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One (2012) 1.22
Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol (2010) 1.20
Lsh participates in DNA methylation and silencing of stem cell genes. Stem Cells (2009) 1.20
Noninvasive monitoring of embryonic stem cells in vivo with MRI transgene reporter. Tissue Eng Part C Methods (2009) 1.19